enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

A WMer's thoughts around the holidays from her to you....

A WMer's thoughts around the holidays from her to you....

Thanksgiving 2020: Home, but not Alone: Has your sense of time shifted lately?  Does avoiding people feel bizarre, and has Purell become your new best friend?  Do you spot beauty in surprising places, and feel the rhythm of your breath inside your mask?

Read more..

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

On October 21, 2020, Dr. Steven Treon gave a webcast lecture to the Canadian National WMFC Patient Support Group. The main topic was genomic & treatment advances in WM, with the discussion also including the related issues surrounding COVID-19.

Read more..

Treatment Advancements are Improving Survivorship and Prompting Hope

Treatment Advancements are Improving Survivorship and Prompting Hope

Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach? Patient Power Co-Founder Andrew Schorr speaks with Dr. Steven Treon, director, Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, about his predictions for the future of Waldenstrom macroglobulinemia treatment.

Read more..

IMS Virtual Workshop November 6-7, 2020

IMS Virtual Workshop November 6-7, 2020

Dr. Steven Treon will be giving a lecture on "New Insights into Waldenstrom's in Session 4 of this virtual Workshop. If you are interested in attending, registration will be closing soon.

Read more..

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

The Eastern Massachusetts IWMF Support Group invites WM/Bing-Neel patients and caregivers from across the globe to join us in the first-ever support group meeting focused on this particularly rare WM complication. With Bing-Neel specialists, Dr. Steve Treon and Dr. Jorge Castillo of Dana-Farber Cancer Institute.

Read more..

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Every two years WM experts from around the world meet to discuss the latest research and developments. The last meeting, IWWM-10 was held in New York in October, 2018, and the consensus recommendations on treatment have just been published in The Lancet. Registration (to read the article) is free.

Read more..

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).

Read more..

The fourth issue of the 21st volume of the IWMF Torch is now online!

The fourth issue of the 21st volume of the IWMF Torch is now online!

If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.

Read more..

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Read more..

IWMF Renews Funding for Pivotal WM Research Project with Dr. Steve Treon

IWMF Renews Funding for Pivotal WM Research Project with Dr. Steve Treon

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) Board of Trustees has reviewed and approved funding an additional $500,000 to renew Dr. Steve Treon's legacy research project.

Read more..